Table 2.
E6 antibody status among individuals who were oral, anal, or genital HPV16 DNA positive during the HIM study.
| HPV16 status | E6 positivea | Total | % E6 positive | 95% CI |
|---|---|---|---|---|
| Oral HPV16 positive | 1 | 28 | 3.6% | 0.0–18.4% |
| Incident oral HPV16 infection | 0 | 17 | 0.0% | 0.0–19.5% |
| Anal HPV16 positive | 1 | 61 | 1.6% | 0.0–8.8% |
| Incident anal HPV16 infection | 0 | 17 | 0.0% | 0.0–19.5% |
| Genital HPV16 positive (2+ year persistent) | 1 | 84 | 1.2% | 0.0–6.5% |
| Incident 2+ year pers. genital HPV16 inf. | 1 | 32 | 3.1% | 0.0–16.2% |
a
E6 seropositivity evident at all three visits for the oral HPV16 infected man (MFI: 3498, 5414, 3466), but only at one visit for the anal HPV16 infected man and the genital HPV16 infected man.